News & Events

Insight into the history of Cardior, its lead compound CDR132L and the €1B acquisition by Novo Nordisk in an hour-long conversation with Philip Hemme in flot.bio - Europe’s Biotech Podcast.

The transaction on the acquisition of Cardior Pharmaceuticals by Novo Nordisk A/S received all regulatory approvals and is officially completed. As of May 2, 2024, Cardior Pharmaceuticals is a fully owned subsidiary of Novo Nordisk A/S. The transition process is now in progress. Novo Nordisk plans to initiate a second phase 2 trial to investigate Cardior’s lead compound in a chronic heart failure population and advance it further towards market approval.

On January 25, 2024 the European Journal of Heart Failure published the article “Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial”. The article provides information on the HF-REVERT Clinical Trial evaluating CDR132L - world’s first RNA therapeutic for the treatment of heart failure.

On December 26, 2023 Journals of American College of Cardiology: Basic to Translational Science Vol. 8 No. 12, 2023 published the article “Development of a Mechanism-Based Next-Generation Therapeutic for Heart Failure Derived from the Dark Genome” by Dr. Janika Viereck, Cardior’s Head of R&D and Prof. Dr. Dr. Thomas Thum, Cardior’s CSO/CMO and Head of the Institute of Molecular and Translational Therapeutic Strategies of Hannover Medical School.” The article offers a detailed summary of the first-ever microRNA-based therapy from the discovery to first-in-human studies and further clinical development.

Cardior’s lead candidate CDR132L is featured in the article “Non-coding RNAs in disease: from mechanisms to therapeutics” published in Nature Reviews Genetics on November 15, 2023. The article by Kinga Nemeth, Recep Bayraktar, Manuela Ferrachin, and George Calin offers a comprehensive summary of our current knowledge of noncoding RNAs and of their roles in major human diseases. It discusses the potential use of RNAs as disease biomarkers and therapeutic targets and lists the most notable clinical research in the field to date.

Cardior Welcomes Leon Carayannopoulos, MD, PhD, as a new Member of the Board of Directors. Leon holds a PhD in Biophysics and has an impressive track record in pharma industry particularly in translational development and clinical pharmacology with the focus on early patient programs for assets including small molecules, biologics, gene therapy, and siRNA. Leon’s vast experience and expertise will be a valuable contribution to Cardior as we continue our HF-REVERT Phase 2 study evaluating our lead candidate, CDR132L, and develop our pipeline further.

CDR132L Mode of Action Video has been released and is now available on Youtube. The purpose of the video is to explain the mechanism of action of our lead candidate CDR132L. 3D Animation allows to visualize the interaction of CDR132L and miR-132 on the cellular level and the effects of such interaction on the heart function.

Our lead candidate, CDR132L, is featured in the article “New Drugs May Help Rebuild Momentum against Cardiovascular Disease” by Tiffany Yesavage published in “Genetic Engineering and Biotechnology News”.

Cardior's lead candidate CDR132L is featured in the article "Genetic medicines aim straight for the heart" by Cormac Sheridan published in Nature Biotechnology on April 04, 2023.

On September 14, 2022, we have officially opened our new headquarters in Hollerithallee 20, 30419 Hanover. Our scientific roots have always been in the Hanover region and we look forward to continuing our international growth from our new headquarters, demonstrating the scientific excellence and entrepreneurial spirit we have experienced in this city.

Cardior’s lead candidate CDR132L has been recognized as the most innovative product in the category “Sprunginnovation” at the Pharma Trend Awards 2022. Listen to our CEO Dr. Claudia Ulrich and CSO Prof. Thomas Thum as they explain the distinct features of CDR132L, Cardior’s approach to cardiac diseases and our evolution as a company.

Cardior's CSO Prof. Dr. Dr. med. Thomas Thum received the Paul Martini Award for the conception and initial testing of a new form of therapy for cardiac insufficiency - also known as heart failure. The prize is awarded annually by the Paul Martini Foundation, Berlin, for outstanding achievements in clinical therapeutic drug research.

Cardior is featured in the BioCentury issue of January 4, 2021 with the “Emerging Company Profile”.

Cardior is featured in the BioWorld issue of January 7, 2019 with the “Newco News”.